ReviewInternational journal for parasitology. Drugs and drug resistance2020
Caenorhabditis elegans in anthelmintic research - Old model, new perspectives.
Review in International journal for parasitology. Drugs and drug resistance, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
50 citing papers in PubMed, 83 citations in OpenAlex.
- Evaluating beta-tubulin variants as predictors of benzimidazole resistance across Caenorhabditis nematodes.PLoS pathogens · 2026Article
- The Use of Piperidinium Surfactants in Nematicide Formulations.Molecules (Basel, Switzerland) · 2026Article
- Spathulenol, a Sesquiterpene fromACS omega · 2026Article
- Chalcone andMolecules (Basel, Switzerland) · 2026Article
- P-glycoproteins and amphids: a two-stage trajectory of ivermectin resistance in Caenorhabditis elegans.International journal for parasitology. Drugs and drug resistance · 2026Article
- Dietary mycotoxin toxicity inAdvances in neurotoxicology · 2026Article
- Chemical perturbation reveals a cytoskeletal-trafficking vulnerability inFrontiers in pharmacology · 2026Article
- Article
- In vitro evaluation of the anthelmintic activity of citrus flavonoids against free-living and parasitic nematodes.Scientific reports · 2025Article
- Resolving tissue and cellular functions of parasitic nematodes.Trends in parasitology · 2025Review
- Pelodera: cosmopolitan phoretic saprotrophs and neglected models for origins of nematode parasitism.Parasites & vectors · 2025Review
- Article
- Drug screens using the nematode Caenorhabditis elegans.Genetics · 2025Review
- Albendazole specifically disrupts microtubules and protein turnover in the tegument of the cestode Mesocestoides corti.PLoS pathogens · 2025Article
- Evaluation of nematode susceptibility and resistance to anthelmintic drugs with a WMicrotracker motility assay.Scientific reports · 2025Article
- Diversity-disease relationships in natural microscopic nematode communities.Royal Society open science · 2025Article
- Microtubule inhibition as a proposed mechanism for the anthelmintic effect of phytochemicals isolated from Cicerbita alpina.Scientific reports · 2025Article
- A new class of natural anthelmintics targeting lipid metabolism.Nature communications · 2025Article
- Resistance to Cry14A family Bacillus thuringiensis crystal proteins in Caenornabditis elegans operates via the nhr-31 transcription factor and vacuolar-type ATPase pathway.PLoS pathogens · 2024Article
- Use of Viscous medium to study anthelmintic drug action in Caenorhabditis elegans.Scientific reports · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
Abstract
For more than four decades, the free-living nematode Caenorhabditis elegans has been extensively used in anthelmintic research. Classic genetic screens and heterologous expression in the C. elegans model enormously contributed to the identification and characterization of molecular targets of all major anthelmintic drug classes. Although these findings provided substantial insights into common anthelmintic mechanisms, a breakthrough in the treatment and control of parasitic nematodes is still not in sight. Instead, we are facing increasing evidence that the enormous diversity within the phylum Nematoda cannot be recapitulated by any single free-living or parasitic species and the development of novel broad-spectrum anthelmintics is not be a simple goal. In the present review, we summarize certain milestones and challenges of the C. elegans model with focus on drug target identification, anthelmintic drug discovery and identification of resistance mechanisms. Furthermore, we present new perspectives and strategies on how current progress in C. elegans research will support future anthelmintic research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.